Yazılar

HealthTap partners with Eli Lilly to expand online diabetes care

/in /tarafından

HealthTap, a U.S. telehealth provider, will join Eli Lilly’s digital healthcare platform LillyDirect to deliver virtual diabetes management services nationwide. The collaboration will give diabetic patients direct access to HealthTap’s primary care physicians, who will oversee treatment, lab reviews, and preventive care tailored to each patient’s needs.

HealthTap’s care model emphasizes continuity with one doctor, allowing long-term, personalized management of chronic conditions like diabetes. CEO Sean Mehra said the partnership leverages Lilly’s growing online presence: “As Lilly markets its website as a destination for consumers, we get to tap into it in a very relevant way.”

The move comes amid surging demand for GLP-1 diabetes and obesity drugs, a market dominated by Lilly and Novo Nordisk. Telehealth providers, pharmacies, and pharmaceutical firms are increasingly teaming up to offer direct-to-consumer digital health services.

Earlier this year, primary care firm knownwell joined LillyDirect to offer similar weight and metabolic health programs. Lilly has also broadened the platform to include telehealth partners for Alzheimer’s care, signaling its ambition to build a one-stop digital health ecosystem.

By joining LillyDirect, HealthTap strengthens its foothold in the rapidly expanding telemedicine and chronic disease management market, as patients increasingly seek accessible, ongoing digital care options.

Olidata Targets Italian M&A Deals to Build Scale, Chairman Says

/in /tarafından

Olidata (OLI.MI), the Italian IT and cybersecurity group, is preparing to expand through mergers and acquisitions, with a potential deal likely before the end of the year, Chairman and main shareholder Cristiano Rufini told Reuters.

Rufini said the focus will remain on the Italian market, where small but innovative tech firms risk losing ground without consolidation. “In Italy, we have some very good, high-performing centres of excellence, but they are very small. If we don’t manage to build significant critical mass, some valuable technologies and solutions risk being lost,” he explained at the TEHA Forum in Cernobbio.

Since returning as chairman in April, Rufini has steered Olidata toward growth in digital healthcare and proprietary cybersecurity technologies. The company reported €96.7 million in revenue and €5.9 million in adjusted EBITDA last year.

Despite being relisted in 2023, Olidata’s share price has been volatile—currently around €2.8 with a €53 million market cap, well below its September 2023 peak of €8.65. Rufini attributed the swings to the stock’s structure, dominated by retail investors holding 32% of capital and the absence of institutional backers.

His goal: build a stronger governance framework, attract institutional investors, and position Olidata as a solid, growth-driven technology player in Italy’s digital economy.